Compare TSLX & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TSLX | HTFL |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2014 | 2025 |
| Metric | TSLX | HTFL |
|---|---|---|
| Price | $22.30 | $30.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $23.50 | ★ $39.50 |
| AVG Volume (30 Days) | 394.9K | ★ 786.5K |
| Earning Date | 02-12-2026 | 03-27-2026 |
| Dividend Yield | ★ 9.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $464,512,000.00 | $161,881,000.00 |
| Revenue This Year | N/A | $40.42 |
| Revenue Next Year | N/A | $22.27 |
| P/E Ratio | $10.78 | ★ N/A |
| Revenue Growth | N/A | ★ 85.70 |
| 52 Week Low | $18.58 | $25.38 |
| 52 Week High | $25.17 | $41.22 |
| Indicator | TSLX | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 45.32 |
| Support Level | $21.73 | $32.80 |
| Resistance Level | $22.60 | $35.98 |
| Average True Range (ATR) | 0.46 | 2.18 |
| MACD | 0.03 | -0.34 |
| Stochastic Oscillator | 80.20 | 6.66 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.